Insud’s Xiromed Rivals Taytulla In US
Follows First-To Market Launch Of Monurol With CGT Designation
Xiromed has announced the introduction of the first generic rival to the Taytulla contraceptive in the US. The launch of Gemmily represents the latest new product for the Insud subsidiary following a busy year.
You may also be interested in...
US-based player Slayback “will kick off a full commercial launch under its own label very soon” of the generic version of Allergan’s Taytulla for which it has just received approval with a competitive generic therapy designation.
Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.
Guidance on protecting participants in bioequivalence studies during the COVID-19 pandemic has been published by the FDA.